Reference only. This page covers what the compound is, how it is presented and how it is handled. It does not give dosing protocols or administration schedules, and it is not medical advice.
What Tirzepatide is
Tirzepatide binds both the GIP and GLP-1 receptors. It sits between the single agonists and retatrutide in receptor coverage, and carries considerably more published data than retatrutide does.
How the pen is supplied
Solution in a sealed 3 ml pen graduated in 300 dial units, held at two strengths.
Pen specification
| Class | Dual agonist, GIP and GLP-1 receptor |
| Also known as | LY3298176 |
| Content | 40 mg |
| Fill volume | 3 ml |
| Dial graduation | 0.01 ml per unit |
| Total dial units | 300 |
| Per dial unit | 133 mcg |
| Cost per mg | £4.38 per mg |
Milligrams per dial unit and cost per milligram are calculated from the pen strength, its fill volume and the current live price. Every SerenQ pen is graduated at 0.01 ml per unit.
Verification
Independent HPLC per batch, identifier printed on the pen.
Stocked at The PED Shop
- SerenQ Tirzepatidein stock£175
Availability checked 2026-09-04. The product page carries live stock.
Common questions
Is tirzepatide a GLP-1?
It acts at the GLP-1 receptor, but not only there. It is a dual agonist, binding GIP as well, which is what distinguishes it from the single agonist compounds.